Abstract

Immune reconstitution syndrome (IRIS) is a state of unusual hyperinflammatory response against latent infections which occurs after CD4 cell count improvement and as a consequence of immune response once highly active antiretroviral therapy for HIV is introduced. Leishmania parasites and varicella zoster virus (VZV) may be a manifestation of IRIS, but few data exist in literature in particular regarding Leishmania parasites. Case Presentation. A 47-year-old man was admitted to our hospital with fever. He was diagnosed with HIV infection and was a late presenter according to CD4+ count of 98 cells/mm3/9.5% and baseline illness (chronic diarrhea, weight loss, and oral candidiasis). The patient started highly active antiretroviral therapy (abacavir plus lamivudine plus efavirenz). Clinical symptoms improved and CD4+ increased to 22%, 374 cells/mm3. After 88 days, he presented with a 17-day history of high fever, sweat, fatigue, further weight loss, and lethargy. According to clinical image findings and hematochemical parameters, the patient was diagnosed with visceral leishmaniasis. He improved under treatment with liposomal amphotericin B. He presented again, 105 days after with disseminated herpes zoster infection. CD4+ count was 28.5%, 455 cell/mm3. The patient started treatment with acyclovir for 10 days. Four weeks later, he had no skin elements. At present, the patient continues HAART and is under regular monitoring. Conclusions. Early diagnosis of IRIS-associated diseases and treatment were fundamental in the patient's prognosis. Our patient presented with two different components of IRIS in two different time frames, confirming IRIS to be a broad-spectrum disease, heterogeneous and unique for each patient. A close monitoring during ART initiation, in particular in late presenters, is important in preventing IRIS. In case of IRIS development, a detailed investigation of rare associated diseases not only common ones is of great importance for the management and the prognosis of these patients.

Highlights

  • Immune reconstitution inflammatory syndrome (IRIS) is a potential complication of highly active antiretroviral therapy (HAART)

  • Following the initiation of HAART, there is an anticipated improvement in the immune-mediated inflammatory response. is unusual hyperinflammatory response is the trademark of IRIS. e prevalence of IRIS is likely to increase with the increasing use of HAART in human immunodeficiency virus (HIV)-infected patients

  • IRIS usually occurs within 6 months of initiation of antiretroviral therapy (ART) in patients with low CD4+ counts and can occur before any marked elevation in CD4+ count is achieved on HAART [4]. e spectrum of infections associated with IRIS is expanding and includes a number of parasitic infections, which may be mediated by different immunopathological mechanisms

Read more

Summary

Introduction

IRIS is a potential complication of highly active antiretroviral therapy (HAART). It was first reported in the 1990s. A few studies reported that up to 25–30% of HIV patients on antiretroviral therapy had IRIS [1, 2]. Mucocutaneous HZ accounts for 7–12% of the diseases related to HIV infection and can reactivate again when the subject’s immunity improves from the administration of HAART. It usually occurs after 4 weeks from the initiation of HAART, and under these circumstances, the clinical symptoms and natural course of mucocutaneous HZ are similar to those in HIV-seropositive subjects who do not manifest IRIS [8]

Case Presentation
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call